Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

NCT ID: NCT02201524


Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-04965842 In Subjects With Moderate To Severe Psoriasis
Purpose
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.
Details
Conditions
Plaque Psoriasis
Keywords
Phase 2, randomized, double-blind, placebo, plaque, psoriasis, safety, efficacy, JAK, janus kinase, moderate, severe
Source
Pfizer
Sponsors
Pfizer
Status
Terminated
Acronym
Last Updated
10 Aug 2016
URL
Official Link
Locations
Canada, United States